NGR-hTNF: Phase II data

Data from 26 evaluable patients in the open-label, Italian Phase II NGR007 trial showed that IV NGR-hTNF plus doxorubicin led to a disease control rate of 54%. Median PFS was 3.2 months. Data were pre...